296 related articles for article (PubMed ID: 16143448)
1. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy.
Nadin SB; Vargas-Roig LM; Drago G; Ibarra J; Ciocca DR
Cancer Lett; 2006 Jul; 239(1):84-97. PubMed ID: 16143448
[TBL] [Abstract][Full Text] [Related]
2. Hsp27, Hsp70 and mismatch repair proteins hMLH1 and hMSH2 expression in peripheral blood lymphocytes from healthy subjects and cancer patients.
Nadin SB; Vargas-Roig LM; Drago G; Ibarra J; Ciocca DR
Cancer Lett; 2007 Jul; 252(1):131-46. PubMed ID: 17276589
[TBL] [Abstract][Full Text] [Related]
3. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
4. Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients.
Magnowska M; Surowiak P; Nowak-Markwitz E; Michalak M; Magnowski P; Rokita W; Kedzia H; Zabel M; Spaczyński M
Ginekol Pol; 2008 Dec; 79(12):826-34. PubMed ID: 19175039
[TBL] [Abstract][Full Text] [Related]
5. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB
Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of DNA repair and expression of MLH1, MSH2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma].
Tronov VA; Artamonov DN; Abramov ME; Gorbacheva LB; Lichinitser MR
Vopr Onkol; 2011; 57(2):165-72. PubMed ID: 21809660
[TBL] [Abstract][Full Text] [Related]
7. Expression of DNA mismatch repair proteins hMSH2 and hMLH1 and the cyclin G1 inhibitor, p21(waf1/cip1) in pediatric tumors: correlation with response to therapy.
Idikio HA
Oncol Rep; 2001; 8(5):965-71. PubMed ID: 11496300
[TBL] [Abstract][Full Text] [Related]
8. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
[TBL] [Abstract][Full Text] [Related]
9. Reduced host cell reactivation of oxidative DNA damage in human cells deficient in the mismatch repair gene hMSH2.
Pitsikas P; Lee D; Rainbow AJ
Mutagenesis; 2007 May; 22(3):235-43. PubMed ID: 17351251
[TBL] [Abstract][Full Text] [Related]
10. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study.
Strom SS; Spitz MR; Yamamura Y; Babaian RJ; Scardino PT; Wei Q
Prostate; 2001 Jun; 47(4):269-75. PubMed ID: 11398174
[TBL] [Abstract][Full Text] [Related]
12. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors.
Olasz J; Mándoky L; Géczi L; Bodrogi I; Csuka O; Bak M
Anticancer Res; 2005; 25(6B):4319-24. PubMed ID: 16309235
[TBL] [Abstract][Full Text] [Related]
13. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
14. Assessment of chemotherapy-induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline comet assay.
Kopjar N; Garaj-Vrhovac V; Milas I
Teratog Carcinog Mutagen; 2002; 22(1):13-30. PubMed ID: 11754384
[TBL] [Abstract][Full Text] [Related]
15. DNA crosslinks, DNA damage and repair in peripheral blood lymphocytes of non-small cell lung cancer patients treated with platinum derivatives.
Fikrova P; Stetina R; Hrnciarik M; Hrnciarikova D; Hronek M; Zadak Z
Oncol Rep; 2014 Jan; 31(1):391-6. PubMed ID: 24154806
[TBL] [Abstract][Full Text] [Related]
16. [Cellular markers based on DNA damage and repair (BER, MMR), expression of MLHI, MSH2, FasR, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma].
Tronov VA; Artamonov DN; Abramov ME; Gorbacheva LB
Tsitologiia; 2011; 53(1):10-6. PubMed ID: 21473113
[TBL] [Abstract][Full Text] [Related]
17. Unbalanced germ-line expression of hMLH1 and hMSH2 alleles in hereditary nonpolyposis colorectal cancer.
Curia MC; Palmirotta R; Aceto G; Messerini L; Verì MC; Crognale S; Valanzano R; Ficari F; Fracasso P; Stigliano V; Tonelli F; Casale V; Guadagni F; Battista P; Mariani-Costantini R; Cama A
Cancer Res; 1999 Aug; 59(15):3570-5. PubMed ID: 10446963
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients.
Johnstone EC; Lind MJ; Griffin MJ; Boddy AV
Cancer Chemother Pharmacol; 2000; 46(6):433-41. PubMed ID: 11138456
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutS homolog 2 in resected esophageal squamous cell carcinoma.
Tzao C; Hsu HS; Sun GH; Lai HL; Wang YC; Tung HJ; Yu CP; Cheng YL; Lee SC
J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1371. PubMed ID: 16256791
[TBL] [Abstract][Full Text] [Related]
20. Differential involvement of the human mismatch repair proteins, hMLH1 and hMSH2, in transcription-coupled repair.
Leadon SA; Avrutskaya AV
Cancer Res; 1997 Sep; 57(17):3784-91. PubMed ID: 9288788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
